GeneDx rose 135-fold on genome tests, then lost 66% on pay fears

Timeline

GeneDx’s three years break into a rescue, a boom and a reset; the chart above marks each turn. Measured over exactly three years, from $3.10 on Oct 23, 2023, the stock is up about 18-fold.

1. Oct 30, 2023: GeneDx cut its 2023 sales forecast as it wound down the Sema4 testing businesses. Two weeks later the shares hit their low, valuing the company at about $32 million.
2. 2024: Results beat the company’s own plans quarter after quarter as exome and genome tests grew to a third of all tests.
3. Oct 29, 2024: GeneDx posted its first adjusted profit, ahead of its 2025 target, and the stock jumped 50% in a day.
4. Apr 30, 2025: Results beat the company’s plan and it raised its forecast, but test volume grew only 24%, below its 30% target for the year. The stock fell 43%.
5. Nov 25, 2025: After a rally on strong quarterly results, new pediatric testing guidelines, an FDA Breakthrough Device designation and new newborn-screening programs, the stock peaked at $167.51.
6. May 4, 2026: GeneDx cut its 2026 sales forecast by about $65 million, mainly because it was being paid less per test. The stock halved the next day.
7. Sep 21, 2026: Medicare proposed lower 2027 rates for exome and genome tests. The stock, which had rebounded to about $105 on Sep 17, was already slipping and has kept falling.

What’s driving it

Company-specific

The rise came from turning a cash-burning merger into a focused, high-margin test business; the fall came from doubts about how much that business gets paid.

GeneDx now earns most of its revenue from exome and genome tests, which pay far more than the single-gene tests it used to run. Adjusted gross margin climbed from 45% in 2023 to 71% in 2025. Volume kept growing as pediatricians, NICUs and more state Medicaid programs adopted the tests. In June 2025 the American Academy of Pediatrics recommended exome or genome sequencing as a first test for children with developmental delay or intellectual disability.

The reset is about price, not demand. Test volume still grew 32% in the second quarter of 2026, but the average payment per test fell 12% from a year earlier, to about $3,250. The company blames mainly the shift toward whole-genome tests, which insurers often pay less for, or not at all, in outpatient care. In May it also wrote down Fabric Genomics, a software business it bought in 2025. Shareholder lawsuits claim the company misled investors about Fabric’s impact on its business.

Sector and market

This is a GeneDx story, not a sector one. Over the same period the S&P 500 and the biotech ETF rose far less, while Natera and Guardant rose strongly and kept rising after GeneDx peaked in November 2025.

What happened today

We found no clear cause for the Oct 23 drop. The stock fell as much as 18% and closed down 16%, on more than three times its average volume. There was no company release, SEC filing or reported analyst change, and peers such as Natera, Guardant and Tempus AI were up. The company’s last news came on Oct 19–20: research presentations at a genetics conference and a plan to add long-read genome sequencing.

The context is a stock already under pressure. It had fallen about 46% since mid-September, a slide that deepened after the Medicare proposal. Third-quarter results are expected soon (no date announced yet; Yahoo Finance estimates Oct 27), CMS’s final rates are due in November, and about 36% of the freely traded shares as Yahoo Finance counts them (about 19% of all shares) were sold short at the end of September, which can magnify swings.

Have the fundamentals changed?

The business is far bigger and healthier than in 2023, but 2026 broke its momentum on revenue and cash.

	2023	2025	2026 so far
Revenue	$203M	$428M	$475–490M forecast
Exome and genome tests	49,439	97,271	+32% (Q2)
Adjusted gross margin	45%	71%	70% (Q2)
GAAP net loss	−$176M	−$21M	−$81M (first half)
Operating cash flow	−$180M	+$33M	−$61M (first half)

2023 revenue is for the total company; continuing operations were $194M. The 2023 margin is for continuing operations.

Revenue growth slowed from about 40% in 2025 to a forecast of about 11–15% this year. The company returned to a small adjusted profit in the second quarter, when it had forecast a loss. Cash and investments were $133.5 million at the end of June, before a further $50 million loan and a $5 million share sale to Blackstone in August, which lifted its Blackstone loan facility to $150 million. The share count rose about 15% over three years.

Where it could go from here

These are other people’s views, not ours.

What analysts and the market think

Wall Street remains positive, but short sellers are betting heavily the other way. All eight analysts in Yahoo Finance’s count rate the stock a buy, with an average target of about $94 ($93.50), roughly two-thirds above the latest close. Estimates are drifting: seven analysts cut their third-quarter profit forecasts in the past month, while 2027 forecasts were mixed.

Trefis takes the opposite view. It argues that cash burn is growing and that GeneDx has relied on borrowing, so its case rests on collecting more on genome claims, which so far is a plan rather than a result. Only about a third of outpatient genome claims were being paid; management is aiming for about 70%.

Is the valuation reasonable?

GeneDx now trades at about 3.8 times sales, down from about 12 times at its 2025 peak. That is well below Natera, Guardant and Tempus AI, which analysts expect to grow at broadly similar rates in 2027, but far above Myriad, a slower-growing genetic-testing company.

Has the long-term story changed?

Demand looks intact; the open question is the price per test. Medicare proposed cutting the main exome and genome codes by 15%, the legal maximum for one year, for 2027, with further cuts possible through 2029; for genome tests, the private-insurer median CMS reported is about 40% below today’s Medicare rate. That matters beyond Medicare: California’s Medicaid program, for example, pays 100% of the Medicare rate for genome tests.

Valuation of GeneDx compared with its history and peers

Company	EV/sales	EV/sales 2027e	Growth 2027e
GeneDx WGS (now)	~3.8×	~2.9×	+24%
GeneDx (Nov 2025 peak)1	~12×	n/a	n/a
Natera NTRA	~21×	~16×	+21%
Guardant Health GH	~20×	~13×	+35%
Tempus AI TEM	~9.0×	~6.5×	+23%
Myriad Genetics MYGN	~0.8×	~0.8×	+5%

The 3–5 year view for long-term investors

Again, these are other people’s forecasts, not ours.

• The consensus expects revenue to grow about 24% in 2027, to roughly $600 million, with profit per share rising to about $1.20 (Yahoo Finance).
• GeneDx is pushing beyond geneticists into general pediatrics, the NICU and prenatal testing. It takes part in the NIH-funded BEACONS newborn genome-screening study and works with Florida’s state-backed Sunshine Genetics Network.
• Coverage is widening: 39 state Medicaid programs now cover outpatient exome or genome tests, and Carelon, the largest lab benefit manager, added genome coverage in June.
• The main risks are lower Medicare and Medicaid rates, insurers that pay for genome tests slowly or not at all, cash burn and debt, the shareholder lawsuit, and rival labs.

What would change the story

Faster payment on genome claims, a softer final Medicare rate or a third quarter that beats guidance would ease the pressure. A final 15% cut, another forecast reduction or continued cash burn would add to it.

Our read

GeneDx fixed its business between 2023 and 2025 and owns a leading position in rare-disease testing. The stock priced in a fast, profitable shift to genome tests, and 2026 has shown that getting paid for them is slower and harder than planned.